NewsBenzingaTD Cowen重申对Revolution Medicines的买入评级，并宣布250美元目标价 TD Cowen重申对Revolution Medicines的买入评级，并宣布250美元目标价 Benzinga 2026.10.21 15:10 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy on Kinder Morgan, Raises Price Target to $40 FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study Dover Q3 2026 Earnings Call Transcript JP Morgan Maintains Overweight on Murphy USA, Lowers Price Target to $626 TD Cowen Maintains Hold on Valero Energy, Raises Price Target to $400 Comcast Calls Rival Broadband Pricing 'Irrational' As Competition Heats Up
